-+ 0.00%
-+ 0.00%
-+ 0.00%

3 Penny Stocks To Watch In October 2026

Simply Wall St·10/20/2026 20:25:33
Listen to the news

With yields on 10 year Treasuries expected to stay above 5% through 2027, borrowing is expensive and many investors are hunting for alternatives to large, rate sensitive stocks. Smaller companies with modest share prices but healthier balance sheets can offer a more measured way to seek upside. This article walks through three financially sturdier, low priced stocks screened for stronger fundamentals.

The three stocks highlighted here offer a compelling starting point if you want exposure to lower risk early-stage businesses with a focus on financial strength. However, if you want the names that matter most, these 133 elite penny stocks are the strongest companies we've found.

UOB-Kay Hian Holdings (SGX:U10)

Overview: UOB-Kay Hian Holdings is a Singapore based brokerage group providing retail stockbroking, margin financing, research, and wider wealth and corporate finance services.

Operations: The group generates around $845 million from securities and futures broking and related services, with most activity in Singapore and Hong Kong.

Market Cap: $2.8b

UOB-Kay Hian Holdings is closely linked to the Financially Fit Penny Stocks theme through its retail stockbroking and margin financing. This is supported by 36.1% net profit margins and a P/E of 9.3x versus higher peer multiples. Investors get exposure to a lower priced broker with these valuation and margin characteristics and a 4.27% dividend yield, although income and risk ultimately hinge on how one unseen pressure shapes its funding resilience.

That unseen pressure on funding resilience makes it worth checking the 4 key rewards and 3 important warning signs (1 is major!) before you decide how UOB-Kay Hian Holdings fits your portfolio story.

SGX:U10 P/E Ratio as at Oct 2026
SGX:U10 P/E Ratio as at Oct 2026

Fufeng Group (SEHK:546)

Overview: Fufeng Group is a Qingdao based producer of fermentation driven food additives such as MSG and starch sweeteners, alongside animal nutrition, amino acids and colloid products.

Operations: Fufeng Group generates about CN¥13.6b from Food Additives and CN¥10.3b from Animal Nutrition, with most revenue from the PRC and the balance overseas.

Market Cap: HK$10.4b

Fufeng Group offers exposure to a penny stock. Food Additives supply the clearest cash flow anchor, even as net margin slipped to 3.7% on roughly flat first half 2026 revenue near CN¥13.8b. A double digit dividend yield leans on less certain free cash flow, leaving investors watching what happens if one unresolved cost pressure keeps squeezing that core MSG engine.

If that squeeze keeps building, the 2 key rewards and 3 important warning signs shows where Fufeng Group’s payout strength and pressure points may be starting to decouple.

SEHK:546 Revenue & Expenses Breakdown as at Oct 2026
SEHK:546 Revenue & Expenses Breakdown as at Oct 2026

NagaCorp (SEHK:3918)

Overview: NagaCorp runs the NagaWorld integrated casino and hotel complex in Cambodia, where gaming operations provide the key cash-flow engine.

Operations: The group generates about $663 million from Casino Operations and $23 million from Hotel and Entertainment, with small inter segment eliminations.

Market Cap: HK$10.6b

NagaCorp sits in the Financially Fit Penny Stocks screener because NagaWorld’s gaming and hospitality cash flows support a smaller cap, lower priced profile backed by strong current profitability and a low 4.4x P/E. This is occurring even as earnings growth has slowed and depends on how one unseen pressure plays out around its all debt funding base.

That all debt structure is the real swing factor, so check the NagaCorp financial health report to see whether NagaCorp’s balance sheet risk is being underpriced.

SEHK:3918 P/B Ratio as at Oct 2026
SEHK:3918 P/B Ratio as at Oct 2026

Seeking Fresh Alternatives Beyond These Picks?

Fresh ideas tend to move first, and late money can end up chasing momentum while better entries remain under the radar for now. Consider reviewing new breakouts before they become widely followed.